Bristol-Myers Squibb Company

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2024-07-16 EDT			5-day change	1st Jan Change
41.2 ^USD	+2.62%		+0.83%	-19.70%

07-16	Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained	MT
07-15	Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM

GlycoEra AG announced that it has received funding from Sofinnova Partners SAS, 5AM Venture Management, LLC, Roche Venture Fund, LimmaTech Biologics AG, Bristol-Myers Squibb Company

January 04, 2024

On January 5, 2024, GlycoEra AG closed the transaction. The company amended the terms of transaction. The transaction included participation from new investor, Bristol-Myers Squibb Company, returning investors, Sofinnova Partners SAS, 5AM Venture Management, LLC, and Roche Venture Fund.

Latest news about Bristol-Myers Squibb Company

Goldman Sachs Trims Price Target on Bristol-Myers Squibb to $55 From $56, Buy Rating Maintained	07-16	MT
Transcript : Bristol-Myers Squibb Company Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 11:00 AM	07-15
UBS Cuts Bristol-Myers Squibb Price Target to $43 From $47, Maintains Neutral Rating	07-12	MT
Redburn Atlantic Adjusts Price Target on Bristol-Myers Squibb to $50 From $54, Maintains Neutral Rating	07-11	MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $41 From $43	07-10	MT
Cartesian Therapeutics, Inc. Appoints Kemal Malik to its Board of Directors	07-02	CI
Bristol-Myers Squibb to Pay $2.7 Million to Settle Potential Anti-Competition Case, Israeli Agency Says	07-01	MT
Eisai Co., Ltd. Agrees to End Its Global Strategic Collaboration with Bristol Myers Squibb for the Co-Development and Co-Commercialization of farletuzumab ecteribulin	07-01	CI
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise	06-27	MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours	06-26	MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees	06-26	MT
Bristol Myers: accelerated approval in colorectal cancer	06-24	CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	06-21	CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval	06-21	MT
US FDA approves Bristol Myers' colorectal cancer therapy	06-21	RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo	06-21	MT
Bristol Myers: application validated for subcutaneous Opdivo	06-21	CF
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo	06-21	CI
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey	06-20	CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors	06-19	CF
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024	06-18	CI
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment	06-18	MT

Chart Bristol-Myers Squibb Company

Duration

Period

More charts

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

2024-07-26 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 01:06 pm

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

40.15 USD

Average target price

52.69 USD

Spread / Average Target

+31.24%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-19.70%	81.39B
ELI LILLY AND COMPANY	+61.53%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.66%	359B
MERCK & CO., INC.	+15.06%	325B
ABBVIE INC.	+9.18%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.67%	177B
PFIZER, INC.	+2.47%	165B

Other Pharmaceuticals

Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

GlycoEra AG announced that it has received funding from Sofinnova Partners SAS, 5AM Venture Management, LLC, Roche Venture Fund, LimmaTech Biologics AG, Bristol-Myers Squibb Company

EPS Revisions